Table 4.
Sensitivity analysis 1 of the relationships between both the eGFR at age 88 years and the decrease in the eGFR 3 years before (between age 85 and 88) and total and cardiovascular (CV) mortality
| |
eGFR slope per year between 85 and 88 years in ml/min/1.73 m²/year |
||||
|---|---|---|---|---|---|
| >-1 | -1 to -2.99 | -3 to -4.99 | <-5 | ||
|
eGFR at age 88 > 60 (n=169) |
|
n=128 |
n=26 |
n=12 |
n=3 |
|
Overall mortality |
1 (ref) |
1.35 (0.81-2.25) |
2.09 (1.07-4.09) |
2.43 (0.74-8.03) |
|
|
CV mortality |
1 (ref) |
1.12 (0.41-3.08) |
3.16 (1.12-8.90) |
8.99 (2.34-34.60) |
|
|
eGFR at age 88 45-59 (n=147) |
|
n=71 |
n=46 |
n=21 |
n=9 |
|
Overall mortality |
1 (ref) |
0.70 (0.43-1.15) |
1.07 (0.56-2.05) |
2.31 (1.06-5.06) |
|
|
CV mortality |
1 (ref) |
0.79 (0.34-1.88) |
0.55 (1.39-2.12) |
2.87 (0.84-9.82) |
|
| eGFR at age 88 < 45 (n=62) | |
n=20 |
n=21 |
n=14 |
n=7 |
|
Overall mortality |
1 (ref) |
0.60 (0.29-1.23) |
0.48 (0.16-1.40) |
1.77 (0.52-6.10) |
|
| CV mortality | 1 (ref) | 0.91 (0.34-2.39) | 0.31 (0.04-2.42) | 4.00 (1.04-15.43) | |
The results are presented as the HR (95% CI) and were adjusted for the eGFR at age 88 and gender. The results are shown with one reference group for each eGFR subgroup.
* No events.